
HER2-Positive Gastrointestinal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Salvage options after T-DXd progression
Experts consider zanidatamab off-label, sequencing strategies, and insurance appeals for HER2-directed salvage therapy.
Play episode from 14:53
Transcript


